Previous 10 | Next 10 |
Endotronix Appoints Industry Veteran Dan Dearen to Board of Directors Expands company's financial expertise during time of growth in advance of commercial launch PR Newswire LISLE, Ill. , March 2, 2021 /PRNewswire/ -- Endotronix, Inc., a digital health and me...
Axonics Modulation Technologies (AXNX) has entered into a strategic alliance with Micro Systems Technologies ((MST)). This strategic alliance expands Axonics’ relationship with MST, with the parties collaborating on the non-rechargeable implantable sacral neuromodulation ((SNM)) d...
Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it has entered into a strategic alliance with Micro Systems Technologies...
The following slide deck was published by Axonics Modulation Technologies, Inc. in conjunction with this event. For further details see: Axonics Modulation Technologies (AXNX) Overview of Bulkamid - Slideshow
Axonics Modulation Technologies, Inc. (AXNX) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Neil Bhalodkar – Vice President of Investor Relations Raymond Cohen – Chief Executive Officer Dan Dearen – President and Chief Financial Officer...
Axonics Modulation Technologies (AXNX): Q4 GAAP EPS of -$0.29.Revenue of $34.8M (+249.7% Y/Y)Press Release For further details see: Axonics Modulation Technologies reports Q4 results
Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported results for the fourth quarter and fisca...
Combination creates a global leader for incontinence solutions Acquisition of Bulkamid is expected to be immediately accretive to Axonics Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializ...
Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report fourth quarter and fiscal year 2020 financi...
Two-year Results from ARTISAN-SNM Study to be Presented at Plenary Session Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatmen...
News, Short Squeeze, Breakout and More Instantly...
Axonics Modulation Technologies Inc. Company Name:
AXNX Stock Symbol:
NASDAQ Market:
Axonics Modulation Technologies Inc. Website:
Axonics, Inc. (NASDAQ: AXNX) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.09% on the day to $68.5. Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulat...
Generated record revenue, gross margin and net income in 2Q24 Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results f...
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...